Enzymatica and Sanofi Consumer Health Care have expanded their current agreement for marketing, distribution, and sales of Enzymatica's mouth spray against the common cold to include Mexico. The first order has been placed, and the mouth spray will be available in pharmacies and retail outlets in Mexico this summer, marketed under one of Sanofi's own brands. The expansion to Mexico increases the market for the collaboration by an additional 130 million consumers, with Enzymatica's mouth spray for the first time being sold across the Atlantic Ocean.

Enzymatica and Sanofi started their cooperation in October 2020 and has since launched the mouth spray with patented barrier technology in France and Italy under Sanofi's own brands. With the agreement now being expanded to include Mexico, the size of the markets included in the agreement doubles from approx. 130 million to approx.

260 million consumers. font-weight:boldThe product will be sold under one of Sanofi's own brands in Mexico, where Sanofi is the market leader within several consumer health care categories. The regulatory approval as a medical device by Cofepris (Mexican health authority) took only four months from application to final approval.